Elderly patients are underrepresented in clinical trials for ischemic heart disease drugs, highlighting a gap between trial populations and real-world disease burden.
Despite the high burden of IHD in elderly adults, the majority of drug trials do not enroll participants reflective of age-related prevalence of the disease.
Bourgeois et al. (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: